Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: Correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications

Journal of Clinical Gastroenterology

Volumn 42, Issue 5, 2008, Pages 481-486

  Erzin, Yusuf ^a   Uzun, Hafize ^a   Celik, Aykut Ferhat ^a   Aydin, Seval ^a   Dirican, Ahmet ^a   Uzunismail, Hulya ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cobalamin; Folate; Homocysteine; Inflammatory bowel disease; Pyridoxine

Indexed keywords

ALBUMIN; COBALAMIN; FOLIC ACID; PYRIDOXINE;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG USE; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RISK FACTOR; SMOKING; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; IMMUNOENZYME TECHNIQUES; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INTESTINES; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PYRIDOXINE; RISK FACTORS; THROMBOEMBOLISM; TURKEY; VITAMIN B 12;

EID: 42449117676     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318046eab0     Document Type: Article

References (41)

1. Dahlback B. Blood coagulation. Lancet. 2000;355:1627-1632.
2. Aichbichler BW, Petritsch W, Reicht GA, et al. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1999;44:852-856.
3. Schapira M, Henrion J, Ravoet C, et al. Thromboembolism in inflammatory bowel disease. Acta Gastroenterol Belg. 1999;62:182-186.
4. Talbot RW, Heppell J, Dozois RR, et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140-145.
5. Jackson LM, O'Gorman PJ, O'Connell J, et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. Q J Med. 1997;90:183-188.
6. Koenigs KP, McPhedran P, Spiro HM. Thrombosis in inflammatory bowel disease. J Clin Gastroenterol. 1987;9:627-631.
7. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165-176.
8. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
9. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
10. Herbert V. Drugs effective in megaloblastic anemias. Cobalamin and folic acid. In: Goodman LS, Gilman A, eds. The Pharmacologic Basis of Therapeutics. 5th ed. New York: Macmillian Publishing; 1975:1324-1349.
11. Hoffbrand AV, Stewart JS, Booth CC, et al. Folate deficiency in Crohn's disease: incidence, pathogenesis, and treatment. Br Med J. 1968;2:71-75.
12. Bousvaros A, Zurakowski D, Duggan C, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr. 1998;26:129-135.
13. Franklin JL, Rosenberg HH. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine). Gastroenterology. 1973;64:517-525.
14. Vasilopoulos S, Saiean K, Emmons J, et al. Terminal ileum resection is associated with higher plasma homocysteine levels in Crohn's disease. J Clin Gastroenterol. 2001;33:132-136.
15. Mahmud N, Molloy A, McPartlin J, et al. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut. 2000;47:456-457.
16. Papa A, De Stefano V, Danese S, et al. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:2677-2682.
17. Romagnuolo J, Fedorak RN, Dias VC, et al. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol. 2001;96:2143-2149.
18. Cattaneo M, Vecchi M, Zighetti ML, et al. High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost. 1998;80:542-545.
19. Oldenburg B, Fijnheer R, van der Griend R, et al. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol. 2000;95:2825-2830.
20. Oldenburg B, Van Tuyl BA, van der Griend R, et al. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci. 2005;50:235-240.
21. Danese S, Sgambato A, Papa A, et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005;100:886-895.
22. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266.
23. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
24. Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971-976.
25. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
26. Bargen JA, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med. 1936;58:17-31.
27. Graef V, Baggenstoss AH, Sauer WG, et al. Venous thrombosis occurring in non-specific ulcerative colitis. A necropsy study. Arch Intern Med. 1966;117:377-382.
28. Hudson M, Chitolie A, Hutton RA, et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut. 1996;38:733-737.
29. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34:247-251.
30. Chiarantini E, Valanzano R, Liotta AA, et al. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 1996;82:137-146.
31. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci. 1995;40:1883-1889.
32. Chamouard P, Grunebaum L, Wiesel ML, et al. Prevalence and significance of anticardiolipin antibodies in Crohn's disease. Dig Dis Sci. 1994;39:1501-1504.
33. Aadland E, Odegaard OR, Roseth A, et al. Free protein S deficiency in patients with Crohn's disease. Scand J Gastroenterol. 1994;29:333-335.
34. Liebman HA, Kashani N, Sutherland D, et al. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology. 1998;115:830-834.
35. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000;35:619-623.
36. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386-389.
37. Halsted CH, Gandhi G, Tamura R. Sulphasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med. 1981;305:1513-1517.
38. Chowers Y, Sela BA, Holland R, et al. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol. 2000;95:3498-3502.
39. 6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol. 2003;98:112-117.
40. 6 are independently associated with a heightened risk of deep-vein thrombosis. Circulation. 2001;104:2442-2446.
41. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204-210.